JP7079937B2 - 肺血管疾患を治療するための組成物および方法 - Google Patents

肺血管疾患を治療するための組成物および方法 Download PDF

Info

Publication number
JP7079937B2
JP7079937B2 JP2018561938A JP2018561938A JP7079937B2 JP 7079937 B2 JP7079937 B2 JP 7079937B2 JP 2018561938 A JP2018561938 A JP 2018561938A JP 2018561938 A JP2018561938 A JP 2018561938A JP 7079937 B2 JP7079937 B2 JP 7079937B2
Authority
JP
Japan
Prior art keywords
gls1
yap
taz
pulmonary
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018561938A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019519533A5 (enExample
JP2019519533A (ja
Inventor
ワイ． チャン，スティーブン
ベルテロ，トーマス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The Brigham and Women's Hospital Inc
Original Assignee
The Brigham and Women's Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Brigham and Women's Hospital Inc filed Critical The Brigham and Women's Hospital Inc
Publication of JP2019519533A publication Critical patent/JP2019519533A/ja
Publication of JP2019519533A5 publication Critical patent/JP2019519533A5/ja
Priority to JP2022079875A priority Critical patent/JP7411967B2/ja
Application granted granted Critical
Publication of JP7079937B2 publication Critical patent/JP7079937B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2018561938A 2016-05-26 2017-05-25 肺血管疾患を治療するための組成物および方法 Active JP7079937B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022079875A JP7411967B2 (ja) 2016-05-26 2022-05-16 肺血管疾患を治療するための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662341848P 2016-05-26 2016-05-26
US62/341,848 2016-05-26
PCT/US2017/034420 WO2017205595A1 (en) 2016-05-26 2017-05-25 Compositions and methods for treating pulmonary vascular disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022079875A Division JP7411967B2 (ja) 2016-05-26 2022-05-16 肺血管疾患を治療するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2019519533A JP2019519533A (ja) 2019-07-11
JP2019519533A5 JP2019519533A5 (enExample) 2020-06-25
JP7079937B2 true JP7079937B2 (ja) 2022-06-03

Family

ID=60412630

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018561938A Active JP7079937B2 (ja) 2016-05-26 2017-05-25 肺血管疾患を治療するための組成物および方法
JP2022079875A Active JP7411967B2 (ja) 2016-05-26 2022-05-16 肺血管疾患を治療するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022079875A Active JP7411967B2 (ja) 2016-05-26 2022-05-16 肺血管疾患を治療するための組成物および方法

Country Status (7)

Country Link
US (2) US10925869B2 (enExample)
EP (2) EP3463574B1 (enExample)
JP (2) JP7079937B2 (enExample)
KR (2) KR20220120711A (enExample)
CN (2) CN115192719B (enExample)
AU (1) AU2017270092B2 (enExample)
WO (1) WO2017205595A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021504342A (ja) * 2017-11-22 2021-02-15 ユニバーシティ オブ ピッツバーグ −オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション Ｙａｐ１／ｗｗｒｔ１阻害組成物およびｇｌｓ１阻害組成物を投与するための組成物および方法
JP2022119825A (ja) * 2016-05-26 2022-08-17 ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 肺血管疾患を治療するための組成物および方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7156856B2 (ja) * 2018-08-21 2022-10-19 国立大学法人富山大学 抗肥満剤
EP3690110B1 (en) 2019-02-01 2021-06-02 LG Electronics Inc. Laundry treating apparatus
EP3690108B1 (en) 2019-02-01 2021-05-12 LG Electronics Inc. Laundry treating apparatus
EP3690109B1 (en) 2019-02-01 2021-05-05 LG Electronics Inc. Laundry treating apparatus
US20220233535A1 (en) * 2019-05-05 2022-07-28 Georgetown University Use of inhibitors of yap/taz for the treatment of cancer
EP3980072A4 (en) * 2019-06-05 2023-06-14 University of Georgia Research Foundation COMPOSITIONS AND METHODS FOR THE PREVENTION OR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION RELATED TO HUMAN IMMUNE DEFICIENCY VIRUS
JP7514508B2 (ja) * 2020-05-19 2024-07-11 国立大学法人鳥取大学 胆道がん治療薬
US12653785B2 (en) * 2020-05-21 2026-06-16 University of Pittsburgh—of the Commonwealth System of Higher Education Compositions and methods for administering a YAP1/WWRT1 inhibiting composition and a GLS1 inhibiting composition
CN116421591A (zh) * 2023-05-10 2023-07-14 哈尔滨医科大学大庆分校 Ldha抑制剂在制备治疗肺动脉高压的药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016077632A2 (en) 2014-11-13 2016-05-19 Buck Institute For Research On Aging Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5798345A (en) 1990-09-21 1998-08-25 Bone Care International, Inc. Method of inhibiting the hyperproliferation of malignant cells
US5707608A (en) 1995-08-02 1998-01-13 Qlt Phototherapeutics, Inc. Methods of making liposomes containing hydro-monobenzoporphyrin photosensitizer
US5756541A (en) 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
US20050119330A1 (en) * 2003-03-17 2005-06-02 Kao Peter N. Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases
US7943179B2 (en) 2003-09-23 2011-05-17 Massachusetts Institute Of Technology pH triggerable polymeric particles
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
US20090202540A1 (en) * 2008-02-11 2009-08-13 Auspex Pharmaceuticals, Inc. Substituted oxazaphosphorines
EP2279267A4 (en) 2008-03-27 2012-01-18 Vascular Biosciences Inc METHOD FOR IDENTIFYING NEW THERAPY CANDIDATES ON GENE EXPRESSION ANALYSIS IN DISEASES RELATED TO VACCINES
KR100963435B1 (ko) 2008-06-19 2010-06-17 한국과학기술연구원 서방형 약물전달 및 조직재생용 덮인 다공성 생분해성고분자 미립구의 제조 방법
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
WO2015138902A1 (en) 2014-03-14 2015-09-17 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
US20170226507A1 (en) 2014-05-05 2017-08-10 The Brigham And Women's Hospital, Inc. Coordinate control of pathogenic signaling by the mir-130/301 family in pulmonary hypertension and fibroproliferative diseases
US20160058759A1 (en) * 2014-07-03 2016-03-03 Board Of Regents, The University Of Texas System Glutaminase inhibitor therapy
WO2016007647A1 (en) 2014-07-09 2016-01-14 The Johns Hopkins University Glutaminase inhibitor discovery and nanoparticle-enhanced delivery for cancer therapy
CN106794233B (zh) * 2014-08-01 2021-11-12 布里格姆及妇女医院股份有限公司 与肺动脉高压的治疗有关的组合物和方法
WO2016054388A1 (en) 2014-10-03 2016-04-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Glutaminase inhibitors
WO2016130889A1 (en) 2015-02-12 2016-08-18 The Johns Hopkins University Inhibition of yap for breaking tumor immune tolerance
WO2017004310A1 (en) 2015-07-02 2017-01-05 Children's Medical Center Corporation Triplet-triplet annihilation-based upconversion
WO2017095751A1 (en) 2015-12-02 2017-06-08 Partikula Llc Compositions and methods for modulating cancer cell metabolism
US10925869B2 (en) * 2016-05-26 2021-02-23 University of Pittsburgh—of the Commonwealth System of Higher Education Compositions and methods for treating pulmonary vascular disease
EP3713569B1 (en) * 2017-11-22 2024-03-13 University of Pittsburgh- Of the Commonwealth System of Higher Education Therapeutic particle comprising a yap1/wwrt1 inhibiting agent and the glutaminase inhibiting agent 2-cyclopropyl-n-[5-(4-{ [5-(2-phenylacetamido)-1,3,4-thiadiazol-2-yl]amino}piperidin-1-yl)-1,3,4-thiadiazol-2-yl] acetamide and use thereof for treating a pulmonary disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016077632A2 (en) 2014-11-13 2016-05-19 Buck Institute For Research On Aging Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Am J Cancer Res，2016年01月01日，6(1)，27-37
Am J Respir Crit Care Med，2016年，Vol 194, Iss 7，866-877
Cell Reports，2015年，13，1016-1032

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022119825A (ja) * 2016-05-26 2022-08-17 ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 肺血管疾患を治療するための組成物および方法
JP2021504342A (ja) * 2017-11-22 2021-02-15 ユニバーシティ オブ ピッツバーグ −オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション Ｙａｐ１／ｗｗｒｔ１阻害組成物およびｇｌｓ１阻害組成物を投与するための組成物および方法
JP7394463B2 (ja) 2017-11-22 2023-12-08 ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション Ｙａｐ１／ｗｗｒｔ１阻害組成物およびｇｌｓ１阻害組成物を投与するための組成物および方法

Also Published As

Publication number Publication date
EP3970720A1 (en) 2022-03-23
JP2019519533A (ja) 2019-07-11
EP3463574A1 (en) 2019-04-10
KR102434879B1 (ko) 2022-08-22
KR20190013926A (ko) 2019-02-11
WO2017205595A1 (en) 2017-11-30
KR20220120711A (ko) 2022-08-30
EP3970720B1 (en) 2023-07-05
JP2022119825A (ja) 2022-08-17
CN109843378A (zh) 2019-06-04
CN109843378B (zh) 2022-06-10
US11672795B2 (en) 2023-06-13
CN115192719A (zh) 2022-10-18
JP7411967B2 (ja) 2024-01-12
AU2017270092A1 (en) 2018-12-06
US20190298710A1 (en) 2019-10-03
CA3025401A1 (en) 2017-11-30
US20210154187A1 (en) 2021-05-27
EP3463574A4 (en) 2020-07-29
US10925869B2 (en) 2021-02-23
CN115192719B (zh) 2024-03-01
AU2017270092B2 (en) 2022-04-14
EP3463574B1 (en) 2021-11-03

Similar Documents

Publication Publication Date Title
JP7411967B2 (ja) 肺血管疾患を治療するための組成物および方法
US20120328629A1 (en) Therapeutic Applications Targeting SARM1
Zhou et al. AIFM1, negatively regulated by miR-145-5p, aggravates hypoxia-induced cardiomyocyte injury
Wei et al. Fibroblast-to-cardiomyocyte lactate shuttle modulates hypertensive cardiac remodelling
WO2019177138A1 (ja) 異常ｔｄｐ－４３を分解除去する抗体断片
CN110538327A (zh) Gpr31抑制剂在制备治疗脂肪代谢异常及相关疾病的药物中的应用
Du et al. Small-molecule activation of TFEB alleviates Niemann–Pick disease type C via promoting lysosomal exocytosis and biogenesis
US9616101B2 (en) Differentiation marker and differentiation control of eye cell
Guadagnin et al. Tyrosine 705 phosphorylation of STAT3 is associated with phenotype severity in TGFβ1 transgenic mice
KR20070085232A (ko) 혈관신생 치료방법
US20250003952A1 (en) Senolytic drug screening method and senolytic drug
Li et al. M3 subtype of muscarinic acetylcholine receptor inhibits cardiac fibrosis via targeting microRNA-29b/beta-site app cleaving enzyme 1 axis
CA3025401C (en) Compositions and methods for treating pulmonary vascular disease
AU2022203624A1 (en) Compositions and methods for treating pulmonary vascular disease
JP2021500078A (ja) 細胞外小胞関連疾患のための材料および方法
HK40006997B (en) Compositions and methods for treating pulmonary vascular disease
EP3132794A1 (en) Composition for promoting remyelination in nerve cells comprising 2,5-dihydroxybenzenesulfonic acid and use thereof
Smith Extracellular Matrix Remodelling in Age-Related Sinus Node Disease
Wabel Vascular Chemerin as a Driver of Obesity-Related Hypertension and Vascular Stiffness
Pereira et al. CDCP1 Deletion Protects Against Pressure Overload-Induced Cardiac Dysfunction and Fibrosis in Mice
Dierschke Impact of Protein O-glcnacylation in Retina: Mechanisms Regulating mRNA Translation and Identification of Novel Therapeutic Targets for Diabetic Retinopathy
Mughal Regulation of mitochondrial function by Myocardin during cardiac development and disease
McAvoy Non-cell Autonomous Toxicity in Motor Neuron Disease: Evidence and Mechanisms of Astrocyte-Driven Neurotoxicity in FUS-ALS
JP2010241694A (ja) 血管新生阻害剤
Bartolomé et al. Pancreatic β-cell failure mediated by mTORC1 hyperactivity and autophagic impairment.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200518

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211012

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220111

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220419

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220516

R150 Certificate of patent or registration of utility model

Ref document number: 7079937

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250